Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced the opening of a state-of-the-art research center in Billerica, MA, establishing it as a “hub” within the Merck KGaA research organization. Representing a $65 million investment, the Billerica research facility supports the company’s commitment to developing and discovering innovative treatments in oncology, neurodegenerative diseases and infertility. Nearly 100 new jobs will be added in Massachusetts as a result of the building expansion.
To view Multimedia News Release, go to
http://multivu.prnewswire.com/mnr/emdserono/48166/
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that the company’s state-of-the-art research center in Billerica, MA, is LEED® Gold certified under the U.S. Green Building Council and verified by the Green Building Certification Institute (GBCI). LEED® is the nation’s preeminent program for the design, construction and operation of high performance green buildings. The Billerica research facility supports the company’s commitment to developing and discovering innovative treatments in oncology, neurodegenerative diseases and fertility, and is one of only five laboratories in Massachusetts to achieve this high rating.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/emdserono/49715/
During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
Now on the web, www.canceranswers123.com offers all the information about cancer in three clicks of a mouse. Medical information, clinical trials, blogs, webcasts, news in real time and video; all available at your reading leisure online at ca123.com or on a mobile app.
The latest in cancer information from the American Cancer Society is located right on the home page to help answer questions, and provide a patient support care network. Another use of the web portal is for medical practitioners who want to easily adapt an oncology specific site for use by their business or medical facility.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46513-Cancer-Answers-123/
Now on the web, www.canceranswers123.com offers all the information about cancer in three clicks of a mouse. Medical information, clinical trials, blogs, webcasts, news in real time and video; all available at your reading leisure online at ca123.com or on a mobile app.
The latest in cancer information from the American Cancer Society is located right on the home page to help answer questions, and provide a patient support care network. Another use of the web portal is for medical practitioners who want to easily adapt an oncology specific site for use by their business or medical facility.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46513-Cancer-Answers-123/
